Caregivers of individuals diagnosed with acute leukemia face a difficult balancing act: meeting the urgent demands of cancer ...

OHSU researchers found that combining venetoclax with breast cancer drug palbociclib strongly improves AML treatment by ...

A research team at Oregon Health & Science University (OHSU) has discovered a promising new drug combination that may help people with acute myeloid leukaemia overcome resistance to one of the most ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Research on mRNA vaccines have been under fire in the post-pandemic age, but these immunotherapies are showing promise in the ...

Amgen acquires Dark Blue Therapeutics for up to $840 million, adding early-stage leukemia drug research and strengthening its oncology discovery pipeline.

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

DNA doesn’t just sit still inside our cells — it folds, loops, and rearranges in ways that shape how genes behave. Researchers have now mapped this hidden architecture in unprecedented detail, showing ...

OXFORD, England, Jan. 6, 2026 /PRNewswire/ -- Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been ...

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...